Table 2.
Cycle no. | 1.3 mg/m2 dose level in the current study (n = 87) n (%) | The global VISTA study (n = 340) n (%) |
---|---|---|
1 | 87 (100) | 340 (100) |
2 | 73 (84) | 305 (90) |
3 | 63 (72) | 284 (83) |
4 | 50 (57) | 266 (78) |
5 | 44 (51) | 249 (73) |
6 | 39 (45) | 236 (69) |
7 | 37 (43) | 224 (65) |
8 | 33 (38) | 213 (62) |
9 | 28 (32) | 202 (59) |
VISTA, Velcade as Initial Standard Therapy in Multiple Myeloma.